Ad
related to: daratumumab janssen
Search results
Results from the WOW.Com Content Network
Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. [9] Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma.
Daratumumab [1] Janssen Biotech: multiple myeloma: Nivolumab [1] Bristol-Myers Squibb: advanced renal cell carcinoma: Elotuzumab [1] Bristol-Myers Squibb: multiple myeloma: Sebelipase alfa [1] Alexion Pharmaceuticals: lysosomal acid lipase deficiency: Alectinib [1] Hoffmann-La Roche: ALK-mutated NSCLC: Pembrolizumab [1] Merck Sharp & Dohme ...
Janssen COVID-19 vaccine [50] Neuroscience therapies Concerta [51] Invega [52] Ponvory [53] Risperdal Consta [54] Spravato [55] Topamax [56] Trevicta [57] Xeplion [58]
In 1961, Johnson & Johnson acquired Janssen Pharmaceuticals, which had been founded in 1953 by Belgian scientist Paul Janssen, [47] the inventor of Fentanyl. [48] In 1963, Philip B. Hofmann succeeded Robert Wood Johnson as chairman and CEO. He was the first non-Johnson family member to become chief executive.
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. [7] The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan.
It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]
Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.
Each antibody binds only one specific antigen. Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines.
Ad
related to: daratumumab janssen